{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:39:07Z","timestamp":1790620747638,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Health Economics"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jhealeco.2020.102408","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T12:16:43Z","timestamp":1606393003000},"page":"102408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences"],"prefix":"10.1016","volume":"75","author":[{"given":"Bokyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhealeco.2020.102408_bib0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addbeh.2017.01.011","article-title":"Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: evidence from the national survey of drug use and health","volume":"69","author":"Ali","year":"2017","journal-title":"Addict. Behav."},{"issue":"4","key":"10.1016\/j.jhealeco.2020.102408_bib0010","first-page":"1","article-title":"Supply-side drug policy in the presence of substitutes: evidence from the introduction of abuse-deterrent opioids","volume":"10","author":"Alpert","year":"2018","journal-title":"Am. Econ. J.: Econ. Policy"},{"issue":"1\u20133","key":"10.1016\/j.jhealeco.2020.102408_bib0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.drugalcdep.2007.09.018","article-title":"Non-medical use, abuse and dependence on prescription opioids among US adults: psychiatric, medical and substance use correlates","volume":"94","author":"Becker","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jhealeco.2020.102408_bib0020","series-title":"The Mitigating Role of Prescription Drug Monitoring Programs in the Abuse of Prescription Drugs","author":"Birk","year":"2017"},{"issue":"1","key":"10.1016\/j.jhealeco.2020.102408_bib0025","first-page":"77","article-title":"The effect of prescription drug monitoring programs on opioid utilization in medicare","volume":"10","author":"Buchmueller","year":"2018","journal-title":"Am. Econ. J.: Econ. Policy"},{"issue":"2","key":"10.1016\/j.jhealeco.2020.102408_bib0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/ecin.12819","article-title":"The effects of recreational marijuana legalization and dispensing on opioid mortality","volume":"58","author":"Chan","year":"2020","journal-title":"Econ. Inq."},{"issue":"5","key":"10.1016\/j.jhealeco.2020.102408_bib0035","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","article-title":"Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin","volume":"72","author":"Cicero","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.jhealeco.2020.102408_bib0040","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamapsychiatry.2014.366","article-title":"The changing face of heroin use in the United States: a retrospective analysis of the past 50 years","volume":"71","author":"Cicero","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"April (4)","key":"10.1016\/j.jhealeco.2020.102408_bib0045","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1257\/aer.104.4.1320","article-title":"Do physicians\u2019 financial incentives affect treatment patterns and patient health?","volume":"104","author":"Clemens","year":"2014","journal-title":"Am. Econ. Rev."},{"issue":"June (8)","key":"10.1016\/j.jhealeco.2020.102408_bib0050","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2105\/AJPH.2014.301923","article-title":"Evolution and convergence of state laws governing controlled substance prescription monitoring programs, 1998\u20132011","volume":"104","author":"Davis","year":"2014","journal-title":"Am. J. Public Health"},{"issue":"1","key":"10.1016\/j.jhealeco.2020.102408_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1162\/rest_a_00755","article-title":"How the reformulation of OxyContin ignited the heroin epidemic","volume":"101","author":"Evans","year":"2019","journal-title":"Rev. Econ. Stat."},{"issue":"1","key":"10.1016\/j.jhealeco.2020.102408_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1162\/qjec.122.1.1","article-title":"The aggregate effects of health insurance: evidence from the introduction of medicare","volume":"122","author":"Finkelstein","year":"2007","journal-title":"Q. J. Econ."},{"issue":"6","key":"10.1016\/j.jhealeco.2020.102408_bib0065","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jhealeco.2007.08.002","article-title":"Custom-made versus ready-to-wear treatments: behavioral propensities in physicians\u2019 choices","volume":"26","author":"Frank","year":"2007","journal-title":"J. Health Econ."},{"issue":"1","key":"10.1016\/j.jhealeco.2020.102408_bib0070","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/pam.22098","article-title":"Mandatory access prescription drug monitoring programs and prescription drug abuse","volume":"38","author":"Grecu","year":"2019","journal-title":"J. Policy Anal. Manag."},{"issue":"9","key":"10.1016\/j.jhealeco.2020.102408_bib0075","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.2014.18514","article-title":"Mandatory use of prescription drug monitoring programs","volume":"313","author":"Haffajee","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jhealeco.2020.102408_bib0080","series-title":"The Problem of Data Quality in Analyses of Opioid Regulation: The Case of Prescription Drug Monitoring Programs","author":"Horwitz","year":"2018"},{"issue":"26","key":"10.1016\/j.jhealeco.2020.102408_bib0085","doi-asserted-by":"crossref","first-page":"667","DOI":"10.15585\/mmwr.mm6526a2","article-title":"Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths-United States, 2002\u20132014","volume":"65","author":"Jones","year":"2016","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.jhealeco.2020.102408_bib0090","series-title":"Opioids for the Masses: Welfare Tradeoffs in the Regulation of Narcotic Pain Medications","author":"Kilby","year":"2015"},{"key":"10.1016\/j.jhealeco.2020.102408_bib0095","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","article-title":"The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction","volume":"36","author":"Kolodny","year":"2015","journal-title":"Annu. Rev. Public Health"},{"key":"10.1016\/j.jhealeco.2020.102408_bib0100","series-title":"Bureau of Justice Assistance Prescription Drug Monitoring Program Performance Measures Report: January 2009 Through June 2012, 2014","author":"Kreiner","year":"2014"},{"key":"10.1016\/j.jhealeco.2020.102408_bib0105","series-title":"The Effect of Prescription Drug Monitoring Programs on Opioid Prescriptions and Heroin Crime Rates","author":"Mallatt","year":"2018"},{"key":"10.1016\/j.jhealeco.2020.102408_bib0110","series-title":"Unintended Consequences of Prescription Monitoring: Policy-Induced Substitution to Illicit Drugs","author":"Mallatt","year":"2019"},{"issue":"4","key":"10.1016\/j.jhealeco.2020.102408_bib0115","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1162\/ajhe_a_00101","article-title":"Prescription drug monitoring programs: the role of asymmetric information on drug availability and abuse","volume":"4","author":"Meinhofer","year":"2018","journal-title":"Am. J. Health Econ."},{"key":"10.1016\/j.jhealeco.2020.102408_bib0120","series-title":"Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States","author":"Muhuri","year":"2013"},{"issue":"5","key":"10.1016\/j.jhealeco.2020.102408_bib0125","first-page":"297","article-title":"State prescription drug monitoring programs and fatal drug overdoses","volume":"23","author":"Nam","year":"2017","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.jhealeco.2020.102408_bib0130","series-title":"Multiple Copy Prescription Programs: State Experiences","author":"OIG","year":"1992"},{"issue":"10","key":"10.1016\/j.jhealeco.2020.102408_bib0135","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2105\/AJPH.2005.071647","article-title":"Opioid analgesic involvement in drug abuse deaths in American metropolitan areas","volume":"96","author":"Paulozzi","year":"2006","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.jhealeco.2020.102408_bib0140","series-title":"Mandating PDMP Participation by Medical Providers: Current Status and Experience in Selected States","author":"PDMP Center of Excellence","year":"2014"},{"key":"10.1016\/j.jhealeco.2020.102408_bib0145","series-title":"PDMP Prescriber use Mandates: Characteristics, Current Status, and Outcomes in Selected States","author":"PDMP Center of Excellence","year":"2016"},{"key":"10.1016\/j.jhealeco.2020.102408_bib0150","series-title":"Essays in the Economics of Risky Health Behaviors","author":"Radakrishnan","year":"2015"},{"issue":"4","key":"10.1016\/j.jhealeco.2020.102408_bib0155","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/ajt.13776","article-title":"Increases in drug and opioid overdose deaths-United States, 2000\u20132014","volume":"16","author":"Rudd","year":"2016","journal-title":"Am. J. Transplant."},{"issue":"7","key":"10.1016\/j.jhealeco.2020.102408_bib0160","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/add.14144","article-title":"Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999\u20132015","volume":"113","author":"Ruhm","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.jhealeco.2020.102408_bib0165","series-title":"Can Policy Affect Initiation of Addictive Substance Use? Evidence from Opioid Prescribing","author":"Sacks","year":"2019"},{"key":"10.1016\/j.jhealeco.2020.102408_bib0170","series-title":"Physician Behavior in the Presence of a Secondary Market: The Case of Prescriptions Opioids. Working Paper","author":"Schnell","year":"2017"},{"key":"10.1016\/j.jhealeco.2020.102408_bib0175","first-page":"1","article-title":"Mental health services administration. Prescription drug monitoring programs: a guide for healthcare providers","volume":"10","author":"Substance Abuse","year":"2017","journal-title":"Brief"},{"key":"10.1016\/j.jhealeco.2020.102408_bib0180","series-title":"Estimating Dynamic Treatment Effects in Event Studies with Heterogeneous Treatment Effects","author":"Sun","year":"2020"}],"container-title":["Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167629620310547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167629620310547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T22:30:51Z","timestamp":1759098651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167629620310547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":36,"alternative-id":["S0167629620310547"],"URL":"https:\/\/doi.org\/10.1016\/j.jhealeco.2020.102408","relation":{},"ISSN":["0167-6296"],"issn-type":[{"value":"0167-6296","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences","name":"articletitle","label":"Article Title"},{"value":"Journal of Health Economics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhealeco.2020.102408","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102408"}}